New cleaning verification test - Rapid analysis with SERS dramatically cuts production downtime
28 Jan 2009
Renishaw Diagnostics (previously D3 Technologies Ltd), a world leading provider of trace level detection technology, is developing a new cleaning verification procedure which cuts swab and rinse analysis time from days to hours, significantly reducing production downtime.
The test utilizes patented Klarite® substrate technology and Surface-Enhanced Raman Spectroscopy (SERS) know-how to provide a powerful new analytical tool to the pharmaceutical industry. It is a simple, easy to adopt procedure which provides highly reproducible results.
Klarite is capable of detecting trace quantities of analytes down to parts per billion levels. In addition, all components in an analytical mixture can be detected simultaneously, overcoming the need to ‘search' for contaminants. A robust calibration curve can be generated so that known analytes can be readily quantified.
Cleaning verification is an important consideration in pharmaceutical production. Stringent cleaning protocols are essential, both for regulatory compliance and contamination control.
Enquiries: Caterina Netti, Head of Operations and Technology (+44 141 5577900)
About Renishaw Diagnostics Ltd
Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases.